<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>79</patient-age><report-id>PHHY2012JP109615</report-id><gender>male</gender><reactions><reaction>Osteonecrosis of jaw</reaction><reaction>Severe periodontitis</reaction><reaction>Intense oral pain</reaction><reaction>Eating disorder</reaction><reaction>Pain of the necrosis-affected area of the jaw</reaction><reaction>Inflammation (redness and bleeding) of the other parts of the oral cavity</reaction><reaction>Pus discharge</reaction><reaction>Fear</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PROSEXOL</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Metastases to bone</indication></indications><patient-age>79</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053213_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134644</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012JP109615</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-26</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-07</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012JP109615</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Shinko</reportergivename>
			<reporterfamilyname>Matsushita</reporterfamilyname>
			<reporterorganization>Nagasaki University Hospital</reporterorganization>
			<reporterstate>Nagasaki Prefecture</reporterstate>
			<reportercountry>JP</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Shinko M.;Shingo I.; Noriko H.; Yoshiya K.; Daiki Y.; Yumiko Y.; et al.,. Experience with Oral Care for Patients with Terminal Stage Prostate Cancer Developing Eating Disorder due to Oral Pain from Bisphosphonate-Related Osteonecrosis of the Jaw. The 17th and the 18th Joint Annual Meeting of the Japanese Society of Dysphagia. 2012;613</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>79</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostate cancer metastatic</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tooth extraction</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Palliative care</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Medical diet</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Osteonecrosis of jaw</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Osteonecrosis of jaw</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteonecrosis of jaw</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Severe periodontitis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Periodontitis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Periodontitis</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Intense oral pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Oral pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oral pain</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Eating disorder</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Eating disorder</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Eating disorder</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pain of the necrosis-affected area of the jaw</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Jaw pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pain in jaw</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Inflammation (redness and bleeding) of the other parts of the oral cavity</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Inflammation</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Inflammation</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pus discharge</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Purulent discharge</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Purulent discharge</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fear</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fear</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fear</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="solution for infusion">Solution For Infusion</drugdosageform>
				<drugadministrationroute code="041">Intravenous drip</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastases to bone</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2003</drugstartdate>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eating disorder</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eating disorder</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fear</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fear</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Inflammation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oral pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oral pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain in jaw</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain in jaw</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Periodontitis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Periodontitis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purulent discharge</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purulent discharge</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PROSEXOL</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2003</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ETHINYLESTRADIOL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012JP109615, is a literature report initially received on 04 Sep 2012 with a follow up report received on 07 Dec 2012. The author discussed about experience with <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>care for patients with terminal stage <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer </Semaphore>developing <Semaphore x="2920838" class="MedDRA LLT" value="Eating disorder" score="1.00" ID="10014062"><Semaphore x="1872836" class="Disease or Finding" value="Eating Disorder" score="1.00" ID="C89332">eating <Semaphore x="2338248" class="Disease or Finding" value="Oral Disorder" score="1.00" ID="C3240">disorder </Semaphore></Semaphore>
     <Semaphore x="3158434" class="MedDRA LLT" value="Oral disorder" score="1.00" ID="10067621">
      </Semaphore></Semaphore>
    <Semaphore x="3158434" class="MedDRA LLT" value="Oral disorder" score="1.00" ID="10067621">
     <Semaphore x="2338248" class="Disease or Finding" value="Oral Disorder" score="1.00" ID="C3240">due to <Semaphore x="2338445" class="Disease or Finding" value="Oral Pain" score="1.00" ID="C78509">oral </Semaphore></Semaphore>
     <Semaphore x="3158866" class="MedDRA LLT" value="Oral pain" score="1.00" ID="10031009">
      <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="3158866" class="MedDRA LLT" value="Oral pain" score="1.00" ID="10031009">
     <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">
      <Semaphore x="2338445" class="Disease or Finding" value="Oral Pain" score="1.00" ID="C78509">pain </Semaphore></Semaphore></Semaphore>from bisphosphonate related <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis of the Jaw</Semaphore>. This report refers to a 79-year old male patient. Concomitant medication included Prosexol (ethinylestradiol) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 2003. The patient received <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.74" ID="242959">Zometa </Semaphore>(zoledronate) for <Semaphore x="1618038" class="Disease or Finding" value="Bone Osteosarcoma" score="1.00" ID="C53707"><Semaphore x="1617834" class="Disease or Finding" value="Bone Neoplasm" score="1.00" ID="C9343">the <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="1.00" ID="C25218">treatment </Semaphore><Semaphore x="1617834" class="Disease or Finding" value="Bone Neoplasm" score="1.00" ID="C9343">of <Semaphore x="2224523" class="Disease or Finding" value="Metastatic Neoplasm" score="1.00" ID="C3261">metastatic <Semaphore x="1618654" class="AnatomicStructure" value="Bone Tissue" score="1.00" ID="C13076">bone </Semaphore><Semaphore x="2432123" class="Disease or Finding" value="Prostate Neoplasm" score="1.00" ID="C3343">tumors </Semaphore>
        </Semaphore>
       </Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="2432123" class="Disease or Finding" value="Prostate Neoplasm" score="1.00" ID="C3343">from <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate </Semaphore></Semaphore>
    <Semaphore x="3207273" class="MedDRA LLT" value="Prostate cancer" score="1.00" ID="10060862">
     <Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">
      <Semaphore x="2429864" class="Disease or Finding" value="Prostate Carcinoma Metastatic to the Lung" score="1.00" ID="C36307">
       <Semaphore x="2429704" class="Disease or Finding" value="Prostate Carcinoma Metastatic to the Bone" score="1.00" ID="C36308">
        <Semaphore x="2429540" class="Disease or Finding" value="Prostate Carcinoma by AJCC v7 Stage" score="1.00" ID="C91233">
         <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">cancer </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>from 2003 (unknown date) at an unknown dose. On an unknown date, the patient had severe <Semaphore x="2390408" class="Disease or Finding" value="Periodontal Disorder" score="1.00" ID="C63743">periodontitis</Semaphore>, <Semaphore x="3162277" class="MedDRA LLT" value="Osteonecrosis of jaw" score="1.00" ID="10064658"><Semaphore x="2351521" class="Disease or Finding" value="Osteonecrosis of Jaw" score="1.00" ID="C63924"><Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis <Semaphore x="1912531" class="Procedure" value="Extraction of Tooth" score="1.00" ID="C51770">of jaw </Semaphore></Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="1912531" class="Procedure" value="Extraction of Tooth" score="1.00" ID="C51770">and <Semaphore x="1537062" class="Procedure" value="Apical Endodontic Surgery" score="1.00" ID="C66854"><Semaphore x="2331139" class="AnatomicStructure" value="Odontogenic Tissue" score="1.00" ID="C33794">tooth </Semaphore>extraction</Semaphore></Semaphore>. In Jun 2009, pus discharge and <Semaphore x="1615518" class="AnatomicStructure" value="Bone Marrow" score="1.00" ID="C12431">bone </Semaphore>resorption due to severe <Semaphore x="2390408" class="Disease or Finding" value="Periodontal Disorder" score="1.00" ID="C63743">periodontal disease </Semaphore>of the upper left canine and second molar were noted. <Semaphore x="2419850" class="Procedure" value="Preservation Procedure" score="1.00" ID="C19232">Preservation </Semaphore>of these <Semaphore x="2331139" class="AnatomicStructure" value="Odontogenic Tissue" score="1.00" ID="C33794">teeth </Semaphore>was not possible, and extraction was needed. After discussion with the patientâ€™s attending <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician</Semaphore>, referring to the relevant <Semaphore x="1996750" class="Disease or Finding" value="Guidewire Across Lesion" score="1.00" ID="C100082">guidelines</Semaphore>, <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.74" ID="242959">Zometa </Semaphore>was suspended for 3 months and <Semaphore x="1537062" class="Procedure" value="Apical Endodontic Surgery" score="1.00" ID="C66854"><Semaphore x="2331139" class="AnatomicStructure" value="Odontogenic Tissue" score="1.00" ID="C33794">tooth </Semaphore>extraction </Semaphore>was carried out. However, <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis of the jaw </Semaphore>developed. About 6 months later, <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis </Semaphore><Semaphore x="2535526" class="AnatomicStructure" value="Smegma" score="1.00" ID="C33574">spread </Semaphore>to the opposite (right) side of the <Semaphore x="2082311" class="AnatomicStructure" value="Jaw Bone" score="1.00" ID="C48821">maxilla </Semaphore>which had not undergone <Semaphore x="1537062" class="Procedure" value="Apical Endodontic Surgery" score="1.00" ID="C66854"><Semaphore x="2331139" class="AnatomicStructure" value="Odontogenic Tissue" score="1.00" ID="C33794">tooth </Semaphore>extraction</Semaphore>, <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">making </Semaphore>denture application <Semaphore x="1849470" class="Procedure" value="Difficulty Concentrating Reading Newspaper or Watching Television" score="1.00" ID="C104307">difficult</Semaphore>. In Aug 2010, the patient was hospitalized to receive <Semaphore x="1673867" class="Procedure" value="Cancer Therapeutic Procedure" score="1.00" ID="C16212">treatment <Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">of <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer</Semaphore></Semaphore></Semaphore>, <Semaphore x="3168252" class="MedDRA LLT" value="Palliative care" score="1.00" ID="10059513"><Semaphore x="2366939" class="Procedure" value="Palliative Therapy" score="1.00" ID="C15292">palliative <Semaphore x="2326798" class="Procedure" value="Nutritional Support" score="1.00" ID="C15433">care </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="2326798" class="Procedure" value="Nutritional Support" score="1.00" ID="C15433">and nutritional </Semaphore>improvement. During hospital stay, the patient developed <Semaphore x="1872836" class="Disease or Finding" value="Eating Disorder" score="1.00" ID="C89332">eating disorder </Semaphore>due to extensive <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis of the jaw </Semaphore>and intense <Semaphore x="2338445" class="Disease or Finding" value="Oral Pain" score="1.00" ID="C78509">oral pain</Semaphore>. The patient was thus referred to our department to receive an <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>care. When <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="1.00" ID="C25218">intervention </Semaphore>was started, the patient was refraining from active <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>ingestion because of the <Semaphore x="2949911" class="MedDRA LLT" value="Fear" score="1.00" ID="10016275">fear </Semaphore>associated with <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore>. <Semaphore x="2661215" class="Procedure" value="Ultrasonography" score="1.00" ID="C17230">We </Semaphore>provided <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>care every day, using the specific cleansing technique with a soft toothbrush and thorough washing with physiological saline. One month later, <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>of the <Semaphore x="3125797" class="MedDRA LLT" value="Necrosis" score="1.00" ID="10028851">necrosis </Semaphore>affected area of the <Semaphore x="3160830" class="MedDRA LLT" value="Osteitis" score="1.00" ID="10031149"><Semaphore x="2082311" class="AnatomicStructure" value="Jaw Bone" score="1.00" ID="C48821">jaw </Semaphore>and <Semaphore x="2055572" class="Disease or Finding" value="Inflammation" score="1.00" ID="C3137">inflammation </Semaphore></Semaphore>(<Semaphore x="2455730" class="Disease or Finding" value="Redness" score="1.00" ID="C4077">redness </Semaphore>and <Semaphore x="2988829" class="MedDRA LLT" value="Haemorrhage" score="1.00" ID="10055798">bleeding</Semaphore>) of the other parts of the <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral cavity </Semaphore>alleviated, allowing the patient to ingest also <Semaphore x="2539154" class="Disease or Finding" value="Solid Glomus Tumor" score="1.00" ID="C51133">solid </Semaphore>foods. Nutritional status improved as the eating and swallowing function improved, accompanied by improvement in QOL as well. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis of jaw </Semaphore>was reported as resolving, while for other events, it was unknown. The seriousness of the events was reported as serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>).Follow up report received on 07 Dec 2012: Updated title and author of the article. Added other events (Intense <Semaphore x="3158434" class="MedDRA LLT" value="Oral disorder" score="1.00" ID="10067621"><Semaphore x="2338248" class="Disease or Finding" value="Oral Disorder" score="1.00" ID="C3240"><Semaphore x="2338445" class="Disease or Finding" value="Oral Pain" score="1.00" ID="C78509">oral pain</Semaphore>, <Semaphore x="2920838" class="MedDRA LLT" value="Eating disorder" score="1.00" ID="10014062"><Semaphore x="1872836" class="Disease or Finding" value="Eating Disorder" score="1.00" ID="C89332">Eating <Semaphore x="3051796" class="MedDRA LLT" value="Jaw disorder" score="1.00" ID="10061257">disorder</Semaphore></Semaphore>
       </Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="3051796" class="MedDRA LLT" value="Jaw disorder" score="1.00" ID="10061257">, <Semaphore x="2949911" class="MedDRA LLT" value="Fear" score="1.00" ID="10016275">Fear</Semaphore>, <Semaphore x="2082311" class="AnatomicStructure" value="Jaw Bone" score="1.00" ID="C48821">Jaw </Semaphore></Semaphore>
    <Semaphore x="3160830" class="MedDRA LLT" value="Osteitis" score="1.00" ID="10031149">
     <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>and <Semaphore x="2055572" class="Disease or Finding" value="Inflammation" score="1.00" ID="C3137">Inflammation</Semaphore></Semaphore>).</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>